TG4010 A therapeutic vaccine against MUC1 expressing tumors

被引：39
|
作者：
Limacher, Jean-Marc [1 ]
Quoix, Elisabeth [2 ]
机构：
[1] Transgene SA, Illkirch Graffenstaden, France
[2] Nouvel Hop Civil, Hop Univ Strasbourg, Strasbourg, France
来源：
ONCOIMMUNOLOGY | 2012年 / 1卷 / 05期
关键词：
non-small cell lung cancer; cancer vaccine; TG4010; biomarker; CELL LUNG-CANCER; IMMUNOTHERAPY; CHEMOTHERAPY; MVA-MUC1-IL2;
D O I：
10.4161/onci.19863
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TG4010 is a therapeutic cancer vaccine based on a viral vector, a modified vaccinia of Ankara (MVA), expressing MUC1 as well as interleukine 2. Today the clinical development is focused on advanced non-small cell lung cancer in combination with first line chemotherapy. Potential biomarkers predictive of activity have been identified.
引用
收藏
页码：791 / 792
页数：2
相关论文
共 50 条
  • [1] TG4010: a vaccine with a therapeutic role in cancer
    Arriola, Edurne
    Ottensmeier, Christian
    IMMUNOTHERAPY, 2016, 8 (05) : 511 - 519
  • [2] Vaccine immunotherapy with MVA-Muc1-IL2 (TG4010) in prostate cancer patients with biochemical failure.
    Dreicer, R
    Ahman, R
    Pantuck, A
    Stadler, WM
    Bizouarne, N
    Acres, B
    Derbij, A
    Limacher, JM
    Squiban, P
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 382S - 382S
  • [3] Tumour immunotherapy against MUC1 expressing tumours using mannan MUC1
    Apostolopoulos, V
    Pietersz, GA
    Acres, B
    Osinski, C
    Thynne, G
    Xing, PX
    Karanikas, V
    Vaughan, HA
    Hwang, L
    Popovski, V
    Lees, C
    Ong, CS
    McKenzie, IFC
    BREAST CANCER - ADVANCES IN BIOLOGY AND THERAPEUTICS, 1996, : 315 - 320
  • [4] Cancer immunotherapy: Phase II clinical studies with TG4010 (MVA-MUC1-IL2)
    Acres, Bruce
    JOURNAL OF BUON, 2007, 12 : S71 - S75
  • [5] MVA-MUC1-IL2 vaccine immunotherapy (TG4010) improves PSA doubling time in patients with prostate cancer with biochemical failure
    Dreicer, R.
    Stadler, W. M.
    Ahmann, F. R.
    Whiteside, T.
    Bizouarne, N.
    Acres, B.
    Limacher, J. -M.
    Squiban, P.
    Pantuck, A.
    INVESTIGATIONAL NEW DRUGS, 2009, 27 (04) : 379 - 386
  • [6] MVA-MUC1-IL2 vaccine immunotherapy (TG4010) improves PSA doubling time in patients with prostate cancer with biochemical failure
    R. Dreicer
    W. M. Stadler
    F. R. Ahmann
    T. Whiteside
    N. Bizouarne
    B. Acres
    J.-M. Limacher
    P. Squiban
    A. Pantuck
    Investigational New Drugs, 2009, 27 : 379 - 386
  • [7] Phase II study of the cancer vaccine TG4010 in metastatic renal cell carcinoma
    Linassier, C
    Oudard, S
    Rixe, O
    Machiels, JP
    Rossi, JF
    Ringeisen, F
    Velu, T
    Banu, E
    Acres, B
    Squiban, P
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 416S - 416S
  • [8] ONT-10, a liposomal vaccine targeting hypoglycosylated MUC1, induces a potent cellular and humoral response and suppresses the growth of MUC1 expressing tumors
    Pestano, Linda A.
    Christian, Brenda
    Koppenol, Sandy
    Millard, Jeff
    Christianson, Gary
    Klucher, Kevin
    Rosler, Rob
    Peterson, Scott R.
    CANCER RESEARCH, 2011, 71
  • [9] A signature of circulating biomarkers correlates with clinical outcome in a randomized phase Ilb trial evaluating the therapeutic vaccine TG4010 in NSCLC patients
    Acres, Bruce
    Marie-Bastien, Berangere
    Grellier, Benoit
    Calmels, Bastien
    Bain, Christine
    Bettinger, Severine
    Tavernaro, Annette
    Halluard, Celine
    Bizouarne, Nadine
    Limacher, Jean-Marc
    Lacoste, Gisele
    Bonnefoy, Jean-Yves
    CANCER RESEARCH, 2009, 69
  • [10] Randomized phase IIb trial evaluating the therapeutic vaccine TG4010 (MVA-MUC1-IL2) as an adjunct to chemotherapy in patients with advanced non-small cell lung cancer (NSCLC)
    Ramlau, R.
    Westeel, V.
    Papai, Z.
    Riviere, A.
    Madroszyk, A.
    Koralewski, P.
    Lacoste, G.
    Acres, B.
    Limacher, J. M.
    Quoix, E.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
12345